NHIA to assess paying hefty price for new hemophilia B gene therapy
Taipei, Aug. 19 (CNA) The National Health Insurance Administration (NHIA) will evaluate including a one-time gene therapy to treat individuals with hemophilia B in the NHI drug reimbursement scheme after it is approved in Taiwan, an NHIA official said Monday.